Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting
Jilong Yang,
Yu Xu,
Yong Chen,
Tao Li,
Xiaowei Zhang,
Tu Hu,
Ruwei Xing,
Yun Yang
Affiliations
Jilong Yang
Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin 300060, China
Yu Xu
Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China
Yong Chen
Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China
Tao Li
Department of Bone and Soft tissue Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China
Xiaowei Zhang
Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Tu Hu
Department of Musculoskeletal Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China
Ruwei Xing
Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin 300060, China
Yun Yang
Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology, Tianjin 300060, China
